Efficace et al evaluated the impact of fatigue on overall survival for a patient with myelodysplasia. The authors are from multiple universities in Europe.


Patient selection: myelodysplastic syndrome


Measure of fatigue: EORTC QLQ-C30 (quality of life questionnaire, core 30, European Organisation for Research and Treatment of Cancer)


In Figure 2, increasing fatigue was associated with increased mortality in 6 months, 1 year and 2 years.


percent mortality within 2 years =

= (0.48 * (fatigue score)) + 43


Additional factors associated with worse overall survival:

(1) high risk by IPSS (on multivariate analysis)

(2) transfusion dependence (on univariate analysis)

(3) advanced age (on univariate analysis)

(4) ECOG performance status >= 2 (on univariate analysis, >= 3 might be more specific)

(5) increased WBC count (in univariate analysis)


To read more or access our algorithms and calculators, please log in or register.